Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 221 participants.
Also called NCT01115855
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 221 participants
- Registry
-
NCT01115855
-
- Other papers using this trial's data
- Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01115855. Randomized; triple masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2016-10-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure
- Acronym
- J-EMPHASIS-HF
- Condition
- Heart Failure
- Intervention (Drug)
- Eplerenone
- Intervention (Drug)
- Placebo
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Record details
- Record id
cardio:ct-nct01115855- Content hash
44e714b50e407718c63d03c5e6345cc50b42b521e858b8afad4cfbd28a1df6e8